Since near patient-testing systems using PCR technology first appeared on the market, the leading IVD market research publisher Kalorama Information has provided sound market estimates and forecasts for their usage. As these systems move from novel to closer to a routine usage, our 2019 update provides essential information for marketers in IVD.

Kalorama’s report is a true look at the clinical market for molecular systems, both CLIA-waived and those CLIA-moderate that can be used in an office visit.  The report incorporates systems in development as of 2019 and updates on competitor laggards in previous editions that have not produced products.

Kalorama’s  Market and Potential for Molecular Point of Care Diagnostic Tests  https://kaloramainformation.com/product/the-market-and-potential-for-molecular-point-of-care-diagnostic-tests-2019/

 provides consensus market views and realistic estimates for this novel field, including:

  • Performance of Systems in the 2018 Flu Season
  • What Percentage of Revenues Will Come Outside of Respiratory
  • Where Will This Market Be in 2023?
  • Who Are the Major Players?
  • What Systems are In Development?
  • Can MDx-POC Survive Immunoassay POC Competition?
  • What is the Tropical Disease Potential and What Products are in the Pipeline?
  • Status of STDs, Hep and Other Tests.
  • Where is the Non-US Market?